H
Horizon Therapeutics PLC
F:HPR
Horizon Therapeutics PLC
F:HPR
Price:
110.2
EUR
Market Closed
Market Cap:
€25.3B
Balance Sheet
Balance Sheet Decomposition
Horizon Therapeutics PLC
Horizon Therapeutics PLC
Balance Sheet Decomposition is not available for
Horizon Therapeutics PLC
Horizon Therapeutics PLC
Balance Sheet
Horizon Therapeutics PLC
Horizon Therapeutics PLC
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
81
|
219
|
860
|
509
|
751
|
959
|
1 076
|
2 080
|
1 580
|
2 353
|
|
| Cash Equivalents |
81
|
219
|
860
|
509
|
751
|
959
|
1 076
|
2 080
|
1 580
|
2 353
|
|
| Total Receivables |
16
|
74
|
210
|
306
|
405
|
465
|
409
|
660
|
633
|
676
|
|
| Accounts Receivables |
16
|
74
|
210
|
306
|
405
|
465
|
409
|
660
|
633
|
676
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
10
|
21
|
23
|
185
|
73
|
55
|
54
|
75
|
226
|
170
|
|
| Other Current Assets |
4
|
11
|
13
|
47
|
39
|
67
|
147
|
256
|
361
|
454
|
|
| Total Current Assets |
111
|
325
|
1 106
|
1 046
|
1 268
|
1 546
|
1 686
|
3 070
|
2 800
|
3 653
|
|
| PP&E Net |
4
|
7
|
14
|
24
|
20
|
20
|
70
|
223
|
368
|
440
|
|
| PP&E Gross |
4
|
7
|
14
|
24
|
20
|
20
|
70
|
223
|
368
|
440
|
|
| Accumulated Depreciation |
3
|
4
|
4
|
8
|
14
|
19
|
26
|
48
|
36
|
59
|
|
| Intangible Assets |
131
|
771
|
1 682
|
2 773
|
2 448
|
1 950
|
1 703
|
1 783
|
3 840
|
3 475
|
|
| Goodwill |
0
|
0
|
254
|
446
|
426
|
414
|
414
|
414
|
1 067
|
1 011
|
|
| Other Long-Term Assets |
7
|
12
|
3
|
3
|
40
|
12
|
564
|
582
|
603
|
536
|
|
| Other Assets |
0
|
0
|
254
|
446
|
426
|
414
|
414
|
414
|
1 067
|
1 011
|
|
| Total Assets |
253
N/A
|
1 114
+341%
|
3 059
+174%
|
4 292
+40%
|
4 202
-2%
|
3 942
-6%
|
4 436
+13%
|
6 073
+37%
|
8 678
+43%
|
9 115
+5%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
10
|
21
|
17
|
53
|
35
|
30
|
22
|
38
|
30
|
156
|
|
| Accrued Liabilities |
32
|
148
|
336
|
542
|
743
|
674
|
692
|
822
|
819
|
777
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
48
|
4
|
8
|
11
|
0
|
0
|
0
|
16
|
16
|
|
| Other Current Liabilities |
1
|
1
|
1
|
3
|
7
|
5
|
10
|
16
|
21
|
0
|
|
| Total Current Liabilities |
43
|
219
|
358
|
606
|
795
|
709
|
723
|
876
|
887
|
949
|
|
| Long-Term Debt |
111
|
297
|
1 133
|
1 800
|
1 891
|
1 897
|
1 353
|
1 003
|
2 555
|
2 547
|
|
| Deferred Income Tax |
3
|
0
|
113
|
297
|
158
|
108
|
94
|
67
|
390
|
342
|
|
| Other Liabilities |
144
|
58
|
142
|
326
|
357
|
39
|
80
|
102
|
173
|
204
|
|
| Total Liabilities |
302
N/A
|
574
+90%
|
1 745
+204%
|
3 028
+74%
|
3 201
+6%
|
2 752
-14%
|
2 251
-18%
|
2 047
-9%
|
4 005
+96%
|
4 042
+1%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
457
|
721
|
681
|
848
|
1 242
|
1 179
|
606
|
216
|
319
|
590
|
|
| Additional Paid In Capital |
410
|
1 270
|
2 002
|
2 120
|
2 249
|
2 375
|
2 798
|
4 246
|
4 373
|
4 474
|
|
| Treasury Stock |
0
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
|
| Other Equity |
2
|
4
|
3
|
3
|
1
|
2
|
2
|
0
|
15
|
13
|
|
| Total Equity |
49
N/A
|
540
N/A
|
1 313
+143%
|
1 264
-4%
|
1 001
-21%
|
1 190
+19%
|
2 185
+84%
|
4 025
+84%
|
4 672
+16%
|
5 072
+9%
|
|
| Total Liabilities & Equity |
253
N/A
|
1 114
+341%
|
3 059
+174%
|
4 292
+40%
|
4 202
-2%
|
3 942
-6%
|
4 436
+13%
|
6 073
+37%
|
8 678
+43%
|
9 115
+5%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
66
|
124
|
160
|
162
|
164
|
169
|
188
|
221
|
227
|
227
|
|
Switch to:
Switch to:
See Also
Discover More
